Literature DB >> 10858355

Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations.

E Hershberger1, E A Coyle, G W Kaatz, M J Zervos, M J Rybak.   

Abstract

Animal models are commonly used to determine the efficacy of various antimicrobial agents for treatment of bacterial endocarditis. Previously we have utilized an in vitro infection model, which incorporates simulated endocardial vegetations (SEVs) to evaluate the pharmacodynamics of various antibiotics. In the present study, we compared four experimental rabbit endocarditis protocols to an in vitro infection model in an effort to determine if these models are comparable. We have evaluated the activity of clinafloxacin, trovafloxacin, sparfloxacin, and ciprofloxacin in rabbit models against Staphylococcus aureus and Enterococcus spp. In vitro models were performed simulating the antibiotic pharmacokinetics obtained in the in vivo studies. Models were dosed the same as rabbit models, and SEVs were evaluated at the same time the rabbit vegetations were examined. Clinafloxacin and trovafloxacin were evaluated against methicillin-susceptible (MSSA1199) and -resistant (MRSA494) strains of S. aureus. Ciprofloxacin was studied against MSSA1199 and MSSA487. Sparfloxacin and clinafloxacin were evaluated against Enterococcus faecium SF2149 and Enterococcus faecalis WH245, respectively. We found that reductions in SEV bacterial density obtained in the in vitro model were similar to those obtained in rabbit vegetations, indicating that the SEV model may be a valuable tool for assessing antibiotic potential in the treatment of bacterial endocarditis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10858355      PMCID: PMC89986          DOI: 10.1128/AAC.44.7.1921-1924.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; S L Barriere; L M Albrecht; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

2.  Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; J R Aeschlimann; H H Houlihan; R C Mercier; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

3.  CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; K C Lamp; E M Bailey; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

4.  Sparfloxacin and clinafloxacin alone or in combination with gentamicin for therapy of experimental ampicillin-resistant enterococcal endocarditis in rabbits.

Authors:  J Vazquez; M B Perri; L A Thal; S A Donabedian; M J Zervos
Journal:  J Antimicrob Chemother       Date:  1993-11       Impact factor: 5.790

5.  Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.

Authors:  B J McGrath; S L Kang; G W Kaatz; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

6.  Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S L Barriere; D R Schaberg; R Fekety
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

  6 in total
  21 in total

1.  Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis/oralis in an Ex Vivo Simulated Endocarditis Vegetation Model.

Authors:  Razieh Kebriaei; Seth A Rice; Kyle C Stamper; Ravin Seepersaud; Cristina Garcia-de-la-Maria; Nagendra N Mishra; Jose M Miro; Cesar A Arias; Truc T Tran; Paul M Sullam; Arnold S Bayer; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis.

Authors:  B J Werth; M E Steed; C E Ireland; T T Tran; P Nonejuie; B E Murray; W E Rose; G Sakoulas; J Pogliano; C A Arias; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

3.  Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model.

Authors:  José M Entenza; Andreas Haldimann; Marlyse Giddey; Sergio Lociuro; Stephen Hawser; Philippe Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

4.  Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis.

Authors:  Kerry L LaPlante; Suzanne Woodmansee
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

5.  Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an In Vitro Pharmacokinetic/Pharmacodynamic Model.

Authors:  Razieh Kebriaei; Katherine L Lev; Kyle C Stamper; Susan M Lehman; Sandra Morales; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

6.  Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae.

Authors:  Megan K Luther; Marios Arvanitis; Eleftherios Mylonakis; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

7.  Native valve Proteus mirabilis endocarditis: successful treatment of a rare entity formulated by in vitro synergy antibiotic testing.

Authors:  Caroline R Brotzki; Kari A Mergenhagen; Zackery P Bulman; Brian T Tsuji; Charles S Berenson
Journal:  BMJ Case Rep       Date:  2016-10-20

8.  Evaluation of daptomycin combinations with cephalosporins or gentamicin against Streptococcus mitis group strains in an in vitro model of simulated endocardial vegetations (SEVs).

Authors:  Juwon Yim; Jordan R Smith; Nivedita B Singh; Seth Rice; Kyle Stamper; Cristina Garcia de la Maria; Arnold S Bayer; Nagendra N Mishra; José M Miró; Truc T Tran; Cesar A Arias; Paul Sullam; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2017-08-01       Impact factor: 5.790

9.  Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with β-Lactams against Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions.

Authors:  Razieh Kebriaei; Seth A Rice; Kavindra V Singh; Kyle C Stamper; An Q Dinh; Rafael Rios; Lorena Diaz; Barbara E Murray; Jose M Munita; Truc T Tran; Cesar A Arias; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

10.  Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model.

Authors:  Dong-Gun Lee; Hye-Sun Chun; Dong-Seok Yim; Su-Mi Choi; Jung-Hyun Choi; Jin-Hong Yoo; Wan-Shik Shin; Moon-Won Kang
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.